|
Jun 20
|
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
|
|
Jun 12
|
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
|
|
Jun 12
|
Ionis doses first subject in Phase III trial of Angelman syndrome therapy
|
|
Jun 11
|
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
|
|
Jun 4
|
Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?
|
|
May 30
|
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?
|
|
May 22
|
Ionis reports success in olezarsen trial for high triglycerides
|
|
Apr 3
|
Ionis to host expert panel discussion on sHTG
|
|
Feb 21
|
Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James
|
|
Feb 20
|
Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now
|
|
Feb 20
|
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
|
|
Feb 20
|
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
|
|
Feb 20
|
Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
|
|
Feb 20
|
Q4 2024 Ionis Pharmaceuticals Inc Earnings Call
|
|
Feb 20
|
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...
|
|
Feb 19
|
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
|
|
Feb 19
|
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
|
|
Feb 19
|
Ionis Pharmaceuticals: Q4 Earnings Snapshot
|
|
Feb 19
|
Ionis reports fourth quarter and full year 2024 financial results
|
|
Feb 18
|
Ionis Pharmaceuticals (IONS): Among Top Insider Stock Buys And Sells In January
|